Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;95(3):275-281.
doi: 10.15386/mpr-2346. Epub 2022 Jul 26.

Thyroid carcinoma associated with other primary neoplasms, a single center study

Katalin Gabora  1 , Ovidiu Bălăcescu  2 , Adrian Trifa  3 , Ana Maria Morariu  3 , Bogdan Pop  3 , Simona Vişan  2   4 , Bogdan Fetica  3 , Andra Piciu  5 , Doina Piciu  1   6
Affiliations

Thyroid carcinoma associated with other primary neoplasms, a single center study

Katalin Gabora et al. Med Pharm Rep. 2022 Jul.

Abstract

Background and aims: Thyroid carcinoma is the most frequent endocrine malignancy. It develops following a complex interaction of environmental and genetic factors. Its incidence is on the rise mostly due to the frequent diagnosis of microcarcinomas (tumor <1 cm). In most cases, it has very good prognosis and survival rates. The incidence of a second primary malignancy in thyroid cancer patients is higher than in the general population. In this article, we focus on the role of BRAF V600E mutation in the development of other primary neoplasms associated with thyroid carcinoma.

Methods: This study was conducted in the department of Nuclear Medicine and Genetics of the "Prof. Dr. Ion Chiricuță" Institute of Oncology of Cluj-Napoca. We evaluated patients with thyroid carcinoma, who were diagnosed and treated for other malignancies such as breast, colorectal, lung cancer and malignant melanoma. In addition, we tested for the BRAF V600E mutation using paraffin samples of patients.

Results: We identified 17 patients that had thyroid carcinoma associated with other primary malignancies. Two of the patients included in the study had three associated primary cancers. The time interval between the diagnoses of two primary neoplasms in the same patient was 6.15 years, with a standard deviation (SD) of 5.39 years. The most common primary tumor associated with thyroid carcinoma in this study was breast cancer. We applied genetic testing for the BRAF V600E mutation in 12 patients. The BRAF V600E mutation positivity rate was 26.9% and most of the cancer associations were metachronous (occurring at least 6 months after thyroid cancer).

Conclusions: The BRAF V600E mutation is an important prognostic factor in the neoplasms included in this study, but its presence is not a predictive factor for the appearance of a metachronous or synchronous associated primary neoplasm to thyroid cancer.

Keywords: BRAF V600E; multiple primary malignancies; neoplasm; thyroid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Type and number of primary cancers associated with thyroid cancer.
Figure 2
Figure 2
Distribution of multiple neoplasms by age groups.
See this image and copyright information in PMC

References

    1. Gaengler S, Andrianou XD, Piciu A, Charisiadis P, Zira C, Aristidou K, et al. Iodine status and thyroid nodules in females: a comparison of Cyprus and Romania. Public Health. 2017;143:37–43. - PubMed
    1. Hsu CH, Huang CL, Hsu YH, Iqbal U, Nguyen PA, Jian WS. Co-occurrence of second primary malignancy in patients with thyroid cancer. QJM. 2014;107:643–648. - PubMed
    1. Atta I, Al Qahtani F. Thyroid, Renal, and Breast Carcinomas, Chondrosarcoma, Colon Adenomas, and Ganglioneuroma: A New Cancer Syndrome, FAP, or Just Coincidence. Case Rep Med. 2016;2016:2928084. - PMC - PubMed
    1. Jelsig AM, Qvist N, Brusgaard K, Nielsen CB, Hansen TP, Ousager LB. Hamartomatous polyposis syndromes: a review. Orphanet J Rare Dis. 2014;9:101. - PMC - PubMed
    1. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17:1277–1288. - PubMed

LinkOut - more resources